BIOCHEMICAL AND PHARMACOLOGICAL COMPARISON OF THROMBOLYTIC AGENTS

The number of thrombolytic drugs for the management of acute myocardia l infarction is rapidly expanding. New agents, some of which are bioch emically modified versions of currently available thrombolytics, will soon arrive in the marketplace. The pharmacologic differences of the n ew drugs are the basis for clinical differences such as enhanced clot lysis and prolonged elimination half-life. Ultimately, these features may result in improved infarct artery patency and patient survival.